23rd American Pharma & Biotech Project, Program and Portfolio Conference

16–18 Oct 2024 | Boston, Massachusetts, United States

Vincent Turula

Senior director Program Management

Lexeo Therapeutics

New York, United States

10 profile visitsSpeakerSpeaker

About me

My organisation

Lexeo Therapeutics

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.

Social media

Speaker sessions (3)

Wednesday, 16 October 2024

16:30 - 17:30

ROUNDTABLE DISCUSSIONS: D. Managing external stakeholders

Format:In-personLocation:Beacon Hill Ballroom
  • Break-Out Sessions

Friday, 18 October 2024

09:30 - 10:00

PANEL DISCUSSION: Capacity planning in resource constrained environment

Format:In-personLocation:Beacon Hill Ballroom
  • Capacity Planning In A ResourceConstrained Environment

11:30 - 12:00

KEYNOTE: Accelerating cell & gene therapies: Outlook of possibilities

Format:In-personLocation:Beacon Hill Ballroom
  • Cell & Gene Therapy Resource Planning And New Modalities